Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1 Mutation Myeloid Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06387069
What this trial is testing

Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Hutchmed 316
Testing effectiveness (Phase 2)Looking for participantsNCT07304011
What this trial is testing

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Who this might be right for
Acute Myeloid Leukemia
University of California, Davis 28
Testing effectiveness (Phase 2)Looking for participantsNCT06717958
What this trial is testing

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Who this might be right for
AMLMDS
Technische Universität Dresden 76
Early research (Phase 1)Active Not RecruitingNCT07411586
What this trial is testing

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
M.D. Anderson Cancer Center 32
Early research (Phase 1)Looking for participantsNCT06543381
What this trial is testing

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 15
Early research (Phase 1)Active Not RecruitingNCT02381886
What this trial is testing

IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Who this might be right for
Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals 166
Early research (Phase 1)Study completedNCT02492737
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies
Agios Pharmaceuticals, Inc. 46
Testing effectiveness (Phase 2)Looking for participantsNCT04493164
What this trial is testing

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02677922
What this trial is testing

Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Celgene 130
Large-scale testing (Phase 3)Looking for participantsNCT05907057
What this trial is testing

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia (AML)
Servier Affaires Médicales 245
Early research (Phase 1)Study completedNCT03564821
What this trial is testing

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Who this might be right for
IDH1 Mutation Myeloid Neoplasms
Massachusetts General Hospital 18
Not applicableUnknownNCT03499912
What this trial is testing

Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy

Who this might be right for
Acute Myeloid Leukemia
National Taiwan University Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT07007949
What this trial is testing

A New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIvosidenib
The First Affiliated Hospital of Soochow University 42
Post-approval studies (Phase 4)Looking for participantsNCT07486713
What this trial is testing

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Who this might be right for
AML (Acute Myeloid Leukemia)GliomaCholangiocarcinoma+1 more
Rigel Pharmaceuticals 16
Not applicableUnknownNCT03204838
What this trial is testing

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Who this might be right for
Acute Myeloid Leukemia (AML)
Hospital General de Mexico 100
Early research (Phase 1)UnknownNCT04272957
What this trial is testing

HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms

Who this might be right for
Acute Myeloid Leukemia
Hutchison Medipharma Limited 75
Not applicableApproved For MarketingNCT03245424
What this trial is testing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Who this might be right for
Acute Myeloid LeukemiaRelapsed Adult AMLRelapsed Pediatric AML
Agios Pharmaceuticals, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Early research (Phase 1)WithdrawnNCT04955938
What this trial is testing

Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Who this might be right for
IDH MutationIDH1 MutationIDH2 Gene Mutation+2 more
University of Chicago
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Next Page